NewAmsterdam Pharma 2025 Q2 Earnings Significant Loss Narrowing

NewAmsterdam Pharma (NAMS) reported its fiscal 2025 Q2 earnings on August 6th, 2025. The company’s results showed a marked improvement in financial performance, with a significant narrowing in losses and a dramatic increase in revenue. While the firm remains unprofitable, the 55.5% reduction in net loss year-over-year signals positive momentum in its financial trajectory.

Revenue
NewAmsterdam Pharma achieved a remarkable 740.1% year-over-year increase in total revenue, rising to $19.14 million in 2025 Q2 from just $2.28 million in 2024 Q2. The surge in revenue was primarily driven by $16.1 million from the second installment of development cost contributions under its license agreement with Menarini. This performance underscores the company's progress in monetizing its key drug candidate, obicetrapib.

Earnings/Net Income
NewAmsterdam significantly narrowed its net loss to $-17.36 million in 2025 Q2, a 55.5% improvement from the $-39.01 million loss in the same period last year. On a per-share basis, the loss decreased to $-0.15 from $-0.41, indicating a 63.4% improvement. Despite these improvements, the company has recorded losses for three consecutive years in the same quarter, reflecting ongoing financial challenges.

Price Action
The stock of NewAmsterdam Pharma experienced a notable surge in the period following the earnings report. Shares jumped 9.10% in the latest trading day, climbed 5.31% over the most recent full trading week, and surged 21.38% month-to-date. This strong price performance aligns with the improved earnings report and positive momentum in its clinical pipeline.

Post-Earnings Price Action Review
A strategy of buying NewAmsterdam Pharma shares following its quarterly revenue raise on the financial report date and holding for 30 days has historically delivered strong returns. Over the past three years, this approach achieved a 92.93% return, outperforming the 55.92% benchmark return by 37.02%. The strategy's CAGR of 28.82% reflects consistent growth, supported by a Sharpe ratio of 0.38, which indicates good risk-adjusted returns. Despite a maximum drawdown of 0.00%, the strategy has shown resilience.

CEO Commentary
Michael Davidson, M.D., CEO of NewAmsterdam, highlighted the company’s strong momentum in the first half of 2025. He emphasized the progress of obicetrapib, noting compelling Phase 3 data reinforcing its LDL-C reduction and suggesting a potential role in neurodegenerative risk mitigation. The CEO also pointed to the positive Alzheimer’s biomarker results from the BROADWAY trial and the planned launch of the Phase 3 RUBENS trial. With a strong balance sheet and commercial readiness, Davidson expressed optimism about delivering a first-in-class LDL-C therapy and creating long-term value for stakeholders.

Guidance
While the company has not explicitly provided forward-looking guidance for future quarters, the CEO expressed confidence in the company’s progress and the potential for regulatory and commercial milestones in the coming months. The continued enrollment of patients in the Phase 3 PREVAIL trial and the regulatory application submission for obicetrapib in Europe indicate a strong path forward.

Additional News
NewAmsterdam announced several significant developments. First, the European marketing authorization application for obicetrapib remains on track for submission in the second half of 2025, with the Menarini partnership progressing well. Second, the company plans to launch the Phase 3 RUBENS trial later in 2025, which will evaluate obicetrapib in combination with ezetimibe for patients with type 2 diabetes and metabolic syndrome. Third, NewAmsterdam recently presented late-breaking data from the BROADWAY and TANDEM trials at the EAS 2025 Congress, with simultaneous publication in The New England Journal of Medicine and The Lancet. Additionally, the BROADWAY trial’s Alzheimer’s disease biomarker analysis demonstrated that obicetrapib significantly reduced plasma p-tau217 levels versus placebo, offering potential insights into its role in neurodegenerative disease.